Septerna, Inc. Increase (Decrease) in Other Noncurrent Liabilities
Septerna, Inc. (SEPN) reported Increase (Decrease) in Other Noncurrent Liabilities of $521.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-06-30 was $421.00K.
- Septerna, Inc. increase (decrease) in other noncurrent liabilities for the quarter ending 2026-03-31 was $100.00K.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month |
|---|---|---|
| 2026-06-30 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $521.00K 10-Q · filed 2026-08-10 |
| 2026-03-31 | $100.00K 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |